Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocare's CRYOcare

This article was originally published in The Gray Sheet

Executive Summary

Cryotherapy surgical system expanded labeling allows for use in targeted ablations of specific portions of a swollen prostate to treat benign prostatic hyperplasia. Endocare reports receipt of 510(k) clearance on April 29 for the indication, which will be assessed through market development studies set to begin in the second quarter. The system, which uses extremely cold temperatures to freeze and destroy selected tissue, was 510(k)-cleared in mid-1995 for ablation of the entire prostate to treat prostate cancer ("The Gray Sheet" June 3, 1996, In Brief)
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009981

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel